Literature DB >> 22593459

Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres.

Cristina Sottani1, Guido Poggi, Pietro Quaretti, Mario Regazzi, Benedetta Montagna, Erica Quaquarini, Marcello Imbriani, Emanuela Leoni, Pamela Di Cesare, Alberto Riccardi, Giovanni Bernardo, Claudio Minoia.   

Abstract

AIM: The purpose of this study was the pharmacokinetic (PK) profile assessment in the serum of patients affected by hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) with drug-eluting beads. PATIENTS AND METHODS: This study included 20 patients, 12 treated with DC Bead® and 8 with HepaSphere Microsphere®, preloaded with epirubicin. No patient randomization was used for the inclusion in one group or in the other. Peripheral blood samples were obtained from all patients after the treatment, until 24 hours past the procedure.
RESULTS: The pharmacokinetic study showed low peak serum epirubicin concentrations with greater drug exposure for the DC Bead® group (p<0.05). The highest drug concentration after microsphere injection was observed at 5 minutes in all 20 patients. In the time interval between 1 and 24 hours after TACE, persisting levels of epirubicin were detected in peripheral blood samples.
CONCLUSION: A persistent and sustained drug elution for both types of microparticles was found.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593459

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  Chemoembolization of hepatocellular carcinoma with HepaSphere™.

Authors:  Katerina Malagari; Anastasia Pomoni; Dimitrios Filippiadis; Dimitrios Kelekis
Journal:  Hepat Oncol       Date:  2015-05-05

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

3.  Systematic Review and Pharmacokinetic Meta-analysis of Doxorubicin Exposure in Transcatheter Arterial Chemoembolization and Doxorubicin-Eluted Beads Chemoembolization for Treatment of Unresectable Hepatocellular Carcinoma.

Authors:  Mohammadreza Zarisfi; Arta Kasaeian; Anna Wen; Eleni Liapi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-05-11       Impact factor: 2.441

4.  Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.

Authors:  Sung-Hua Chiu; Ping-Ying Chang; Yu-Lueng Shih; Wen-Yen Huang; Kai-Hsiung Ko; Wei-Chou Chang; Guo-Shu Huang
Journal:  Drug Des Devel Ther       Date:  2020-11-17       Impact factor: 4.162

5.  MRI Findings and Prediction of Time to Progression of Patients with Hepatocellular Carcinoma Treated with Drug-eluting Bead Transcatheter Arterial Chemoembolization.

Authors:  Seungsoo Lee; Kyung Ah Kim; Mi-Suk Park; Sun Young Choi
Journal:  J Korean Med Sci       Date:  2015-06-10       Impact factor: 2.153

Review 6.  Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Jeong Eun Song; Do Young Kim
Journal:  World J Hepatol       Date:  2017-06-28

Review 7.  Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Lin Li; Wenzhuo Zhao; Mengmeng Wang; Jie Hu; Enxin Wang; Yan Zhao; Lei Liu
Journal:  BMC Gastroenterol       Date:  2018-09-04       Impact factor: 3.067

Review 8.  Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma.

Authors:  Yasir M Nouri; Jin Hyoung Kim; Hyun-Ki Yoon; Heung-Kyu Ko; Ji Hoon Shin; Dong Il Gwon
Journal:  Korean J Radiol       Date:  2018-12-27       Impact factor: 3.500

9.  Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.

Authors:  Shilong Han; Xiaoping Zhang; Liling Zou; Chenhui Lu; Jun Zhang; Jue Li; Maoquan Li
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

10.  Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy.

Authors:  V L Bishay; K Maglione; R Khanna; K M Lee; A M Fischman; R A Lookstein; E Kim
Journal:  J Hepatocell Carcinoma       Date:  2014-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.